Neurofibromatosis (NF1 & NF2)

1. Clinical Overview

Neurofibromatosis encompasses two distinct autosomal dominant neurocutaneous disorders: neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2). NF1, also known as von Recklinghausen disease, is the most common phakomatosis, affecting 1 in 3,000-4,000 individuals. It results from mutations in the NF1 gene on chromosome 17, encoding neurofibromin, a tumor suppressor protein. NF2 is rarer (1 in 25,000-40,000) and results from mutations in the NF2 gene on chromosome 22, encoding merlin. Both conditions cause multiple tumors and systemic manifestations, requiring lifelong multidisciplinary monitoring and management.

Clinical Pearls:

• NF1 is one of the most common genetic disorders
• 50% of NF1 cases are de novo mutations (no family history)
• Café-au-lait spots appear in 95% of NF1 patients by age 2
• Lisch nodules (iris hamartomas) are pathognomonic for NF1
• NF2 is characterized by bilateral vestibular schwannomas (acoustic neuromas)

Red Flags:

• Malignant peripheral nerve sheath tumor (MPNST): 5-10% lifetime risk in NF1
• Optic pathway glioma: 15-20% of NF1 patients, most common in childhood
• Pheochromocytoma: 0.1-5.7% of NF1 patients, causes hypertension
• Rapidly growing neurofibroma: Suggests malignant transformation
• Hearing loss in NF2: From bilateral vestibular schwannomas

Image: NF1 vs NF2

Image

2. Epidemiology

NF1 and NF2 are genetic disorders with distinct epidemiological profiles. Understanding prevalence and inheritance patterns guides diagnosis and genetic counseling.

NF1 Epidemiology:

• Prevalence: 1 in 3,000-4,000 live births
• Incidence: 1 in 2,500-3,000 births
• Inheritance: Autosomal dominant, 50% de novo
• Penetrance: 100% by age 20, but variable expressivity
• Gender: Equal distribution

Image: Inheritance Pattern

Image

NF2 Epidemiology:

• Prevalence: 1 in 25,000-40,000
• Incidence: 1 in 33,000-40,000 births
• Inheritance: Autosomal dominant, 50% de novo
• Penetrance: 95% by age 60
• Gender: Equal distribution

Geographic Variation:

• Similar prevalence worldwide
• No clear ethnic predilection
• Familial clustering in some populations

Demographic Nuances:

• Race/Ethnicity: No predilection, but diagnosis is often delayed in Black/Asian patients because café-au-lait spots are harder to distinguish from normal pigment.
• Socioeconomic: Lower SES correlates with higher tumor burden (likely ascertainment bias or lack of access to care).

Mortality Deep Dive:

• Median Age at Death: 54 years (NF1) vs 70 years (General Population).
• Causes of Death:
  1. Malignancy (MPNST): The #1 killer.
  2. Vascular: Stroke/Hypertension (young age).
  3. Glioma: Though often benign, high grade gliomas occur.

Morbidity Impact:

• Cosmetic Severity: Assessed by the Ablon Scale. Severe disfigurement leads to social isolation (> 60% unemployment rates).
• Pain: Chronic neuropathic pain affects 30% of patients.

3. Pathophysiology

NF1 and NF2 result from loss-of-function mutations in tumor suppressor genes, leading to uncontrolled cell growth and tumor formation through distinct molecular pathways.

The Molecular Cascade (7 Steps):

Step 1: The Germline Hit (Haploinsufficiency)

• Mechanism: The patient starts life with one mutated copy of NF1 (17q11.2) in every cell.
• Consequence: Neurofibromin levels are 50% of normal.
• Clinical: This haploinsufficiency causes the mild features (Short stature, Learning (GABAergic inhibitory deficits), Macrocephaly).

Step 2: The Somatic Hit (Loss of Heterozygosity)

• Mechanism: A random "Second Hit" occurs in a specific neural crest cell (Schwann cell precursor).
• Consequence: The cell now has ZERO functional Neurofibromin.
• Clinical: This is the seed for tumor formation.

Step 3: RAS Hyperactivation (The Engine)

• Mechanism: Neurofibromin normally accelerates RAS-GTP hydrolysis (Turn off). Without it, RAS remains in the active GTP-bound state.
• Consequence: Constitutive activation of downstream effectors:
  • RAF-MEK-ERK (Proliferation).
  • PI3K-AKT-mTOR (Survival).

Step 4: The Microenvironment (Mast Cell Recruitment)

• Mechanism: The null-Schwann cells secrete Kit-Ligand (Stem Cell Factor).
• Consequence: This recruits Mast Cells (Heterozygous) to the tumor site.
• Synergy: Mast cells secrete TGF-beta and VEGF, promoting tumor growth and collagen deposition (Fibroma).

Step 5: Angiogenesis and Stromal Reaction

• Mechanism: VEGF upregulation drives new vessel formation.
• Consequence: Pathological blood vessels form (fragile, leaky). Fibroblasts lay down collagen.
• Clinical: The tumor becomes firm and vascular (Plexiform).

Step 6: Malignant Transformation (The Epigenetic Shift)

• Mechanism: In a subset of Plexiforms (8-13%), additional hits occur.
• Targets: Mutations in TP53 (Cell cycle) and CDKN2A (p16).
• Consequence: Introduction of PRC2 (Polycomb) mutations leading to a complete loss of growth control.
• Clinical: Conversion to MPNST (Sarcoma).

Step 7: Systemic Disruption (Metabolic & Vascular)

• Mechanism: RAS activation in smooth muscle and endothelium.
• Consequence: Vascular proliferation (Moyamoya, Renal Artery Stenosis) and bone dysplasia (Osteopenia).

Advanced Genetics (The "Engine Room")

• The RAS-MAPK Pathway:
  • Normal State: Neurofibromin (the protein) acts as a "Brake" on the RAS pathway. It converts active RAS-GTP into inactive RAS-GDP.
  • Disease State: The mutation breaks the "Brake". The engine (RAS) runs uncontrolled.
  • "Result: Constant downstream signalling (RAF -> MEK -> ERK) -> Proliferation."
  • "Therapeutic Target: MEK Inhibitors (Selumetinib) work by blocking this overactive pathway downstream."

Genotype-Phenotype Correlations

While most NF1 is variable, some specific mutations predict the future:

1. NF1 Microdeletion Syndrome (5-10%):
   • Defect: Missing the entire NF1 gene and surrounding genes (1.4Mb deletion).
   • Phenotype: Severe.
   • Features: Dysmorphic facial features, severe developmental delay, early onset/high burden of neurofibromas, high risk of MPNST.
   • Management: Needs aggressive surveillance.
2. 3-bp Deletion (p.Met992del):
   • Phenotype: Mild.
   • Features: Pigmentary features ONLY (Café-au-lait + Freckling). NO neurofibromas.
   • Relevance: Good prognosis.
3. Spinal NF1:
   • Phenotype: Missense mutations.
   • Features: Bilateral spinal neurofibromas (symptomatic) but few cutaneous signs.

Mosaicism (Segmental NF1)

• Concept: The mutation occurs after conception (post-zygotic).
• Result: Only a part of the body is affected (chromosomal mosaicism).
• Presentation: Unilateral or localized Café-au-lait spots/neurofibromas (e.g., just the Left arm).
• Risk: Risk of passing to offspring is low (unless germline mosaicism exists).

Knudson's "Two-Hit" Hypothesis

Why do tumors form?

1. Hit 1 (Germline): Child inherits one broken copy of NF1 from parent (or de novo). Every cell in their body has 1 working copy and 1 broken copy. They are normal (Heterozygous).
2. Hit 2 (Somatic): A random mutation breaks the second (working) copy in a specific Schwann cell.
3. Result: That cell has ZERO working neurofibromin (Null). It grows uncontrollably -> Neurofibroma.
4. Implication: This is why skin bumps appear over time (as random hits accumulate).

NF2 Pathophysiology Steps:

1. NF2 Gene Mutation: Loss-of-function mutations in NF2 gene (chromosome 22q12) encoding merlin (moesin-ezrin-radixin-like protein), a tumor suppressor

2. Merlin Loss: Merlin normally inhibits cell proliferation by interacting with multiple signaling pathways (PI3K-AKT, mTOR, Hippo)

3. Schwann Cell Proliferation: Loss of merlin in Schwann cells leads to uncontrolled proliferation, forming schwannomas (vestibular, spinal, peripheral)

4. Meningeal Cell Growth: Meningeal cells lacking merlin form multiple meningiomas

5. Ependymal Cell Effects: Ependymal cell dysfunction leads to ependymomas

6. Bilateral Vestibular Schwannomas: Characteristic feature, causing hearing loss, tinnitus, and balance problems

7. Tumor Progression: Multiple tumors develop throughout life, requiring surgical intervention and monitoring

Risk Factors

Non-Modifiable Risk Factors:

• Genetic: Autosomal dominant inheritance, 50% risk if parent affected
• De novo mutations: 50% of NF1, 50% of NF2 cases
• Age: Manifestations increase with age
• Gender: Equal distribution in both types

Genetic Factors:

• NF1 mutations: > 3,000 different mutations identified
• NF2 mutations: Various mutation types (nonsense, frameshift, splice site)
• Mosaicism: Mosaic NF1/NF2 may have milder phenotype
• Genotype-phenotype: Some correlations, but variable expressivity

Modifiable Risk Factors:

• None clearly established
• Early diagnosis: Enables monitoring and intervention
• Regular surveillance: Reduces complications

Protective Factors:

• Genetic counseling: Informed family planning
• Prenatal diagnosis: Available for known mutations
• Preimplantation genetic testing: Available for NF1 and NF2

4. Clinical Presentation

Clinical features differ significantly between NF1 and NF2. NF1 presents with cutaneous and neurological manifestations, while NF2 primarily affects the nervous system.

NF1 Clinical Features:

Cutaneous Manifestations:

• Café-au-lait spots: > 6 spots > 5mm (prepubertal) or > 15mm (postpubertal), present in 95% by age 2
• Axillary/inguinal freckling: Present in 80-90%, appears age 3-5
• Neurofibromas: Cutaneous (dermal) and subcutaneous, increase with age
• Plexiform neurofibromas: 30-50% of patients, may be disfiguring
• Detailed Distinctions:
  • Cutaneous (Discrete): Soft, distinct, move with the skin ("Buttonholing"). Benign.
  • Subcutaneous: Firm, tender, deep to skin.
  • Plexiform: "Bag of worms". Diffuse. Involve multiple nerve fascicles. High risk of malignant change.
  • Diffuse: Plaque-like thickening of skin.
• UBOs (Unidentified Bright Objects):
  • Seen on T2 MRI in 60-70% of children.
  • Pathology: Vacuolic myelin degeneration (spongiform change).
  • Locations: Cerebellum, Brainstem, Basal Ganglia.
  • Relevance: They disappear in adulthood. They do NOT cause focal deficits (unlike tumors).

Image: Café-au-lait Spots

Image

Ocular Features:

• Lisch nodules: Iris hamartomas, pathognomonic, present in 90% by age 20
• Optic pathway glioma: 15-20% of patients, most asymptomatic
• Choroidal abnormalities: Present in some patients

Image: Lisch Nodules

Image

Advanced Ocular Findings:

• Lisch Nodules:
  • Appearance: Dome-shaped gelatinous masses on the iris. Yellow-brown.
  • Detection: Slit lamp is essential. They are hard to see with the naked eye.
  • Pathology: Hamartomas of melanocytes. They do NOT affect vision.
• Choroidal Abnormalities (CNA):
  • New Finding: Frequent in NF1 (80%).
  • Detection: Best seen on Infrared Imaging (OCT). Bright patches.
  • Relevance: Often appear before Lisch nodules, aiding early diagnosis in children.
• Optic Pathway Glioma (OPG):
  • Presentation: Proptosis, Decreased Acuity, Precocious Puberty (hypothalamic involvement).
  • Screening: Annual Ishihara and Acuity in children. MRI if symptomatic.

Neurological Features:

• Learning disabilities: 30-60% of patients
• ADHD: 30-50% prevalence
• Seizures: 4-7% of patients
• Macrocephaly: 30-50% of patients

Skeletal Features:

• Scoliosis: 10-26% of patients.
  • Dystrophic: Sharp angulation, short segment. Rapid progression. Needs surgery.
  • Non-Dystrophic: Like idiopathic scoliosis. Brace/Watch.
• Tibial Pseudarthrosis: 2-5% of patients.
  • Mechanism: Anterolateral bowing of the tibia present at birth.
  • Pathology: The bone is dysplastic. If it fractures, it refuses to heal (False Joint = Pseudarthrosis).
  • Management: Protection (bracing). If fracture occurs -> BMPs/Rodding/Amputation.
• Sphenoid Wing Dysplasia:
  • Sign: Pulsatile Exophthalmos (The brain pushes the eye forward because the bone behind the eye is missing).

NF2 Clinical Features:

Vestibular Schwannomas:

• Bilateral: Present in 95% of patients
• Hearing loss: Progressive, unilateral or bilateral
• Tinnitus: Common symptom
• Balance problems: From vestibular dysfunction

Other Nervous System Tumors:

• Meningiomas: Multiple, intracranial and spinal
• Spinal schwannomas: Multiple, may cause cord compression
• Ependymomas: Intramedullary spinal tumors
• Peripheral schwannomas: Multiple

Ocular Features:

• Cataracts: Juvenile posterior subcapsular cataracts
• Retinal hamartomas: Present in some patients
• No Lisch nodules: Distinguishes from NF1

Skin Features:

• Café-au-lait spots: Fewer than NF1, usually less than 6
• Skin tumors: Schwannomas, not neurofibromas
• No axillary freckling: Distinguishes from NF1

5. Clinical Examination

Comprehensive examination identifies diagnostic criteria, monitors for complications, and guides management. Different examination focuses for NF1 vs NF2.

NF1 Examination:

Cutaneous Examination:

• Café-au-lait spots: Count and measure, > 6 required for diagnosis
• Axillary/inguinal freckling: Look in skin folds
• Neurofibromas: Count, measure, document location
• Plexiform neurofibromas: Palpate for deep lesions, assess size

Ophthalmological Examination:

• Slit lamp: Look for Lisch nodules (iris hamartomas)
• Visual acuity: Screen for optic pathway glioma
• Visual fields: If optic pathway involvement suspected
• Fundoscopy: Look for choroidal abnormalities

Neurological Examination:

• Cognitive assessment: Screen for learning disabilities
• Seizure history: Ask about episodes
• Head circumference: Measure for macrocephaly
• Neurological deficits: From tumors or neuropathies

Skeletal Examination:

• Spine: Look for scoliosis, kyphosis
• Limbs: Check for pseudarthrosis, bowing
• Skull: Palpate for defects

Blood Pressure:

• Measure: Screen for pheochromocytoma
• If elevated: Further investigation needed

NF2 Examination:

Cranial Nerve Examination:

• Hearing: Audiometry, speech discrimination
• Facial nerve: Weakness from schwannoma compression
• Trigeminal: Sensory loss, weakness
• Lower cranial nerves: Assess swallowing, voice

Neurological Examination:

• Balance: Romberg, gait assessment
• Motor: Weakness from spinal tumors
• Sensory: Deficits from spinal involvement
• Reflexes: May be abnormal with spinal lesions

Ophthalmological Examination:

• Slit lamp: Look for cataracts
• Fundoscopy: Retinal hamartomas
• Visual fields: If optic nerve involvement

Skin Examination:

• Café-au-lait spots: Usually less than 6
• Schwannomas: Palpable subcutaneous tumors
• No neurofibromas: Distinguishes from NF1

6. Investigations

Diagnostic evaluation confirms NF1 or NF2, monitors for complications, and guides management. Genetic testing confirms diagnosis and enables family screening.

NF1 Diagnostic Criteria (2021 Revision):

• Replaced the old 1987 NIH criteria.
• Requirement: Two or more of:
  1. Café-au-lait Macules: ≥6 (> 5mm if prepubertal, > 15mm if postpubertal).
  2. Freckling: Axillary or Inguinal.
  3. Neurofibromas: ≥2 of any type or ≥1 Plexiform.
  4. Optic Pathway Glioma.
  5. Iris Lisch Nodules: ≥2 OR Choroidal Abnormalities (New addition).
  6. Bone Lesion: Sphenoid dysplasia or Tibial dysplasia.
  7. Genetic Mutation: Heterozygous pathogenic NF1 variant VAF > 50% (New addition).
  8. Relative: First-degree relative meeting criteria.

The Differential: Legius Syndrome

• Gene: SPRED1 mutation.
• Signs: They have the spots (Café-au-lait + Freckling) but NO tumors (No neurofibromas, No Lisch nodules, No Gliomas).
• Relevance: Much better prognosis. They do not get MPNST.
• Diagnosis: Genetic testing is the only way to distinguish phenotypically in childhood.

NF2 Diagnostic Criteria:

• Bilateral vestibular schwannomas, OR
• First-degree relative with NF2 AND unilateral vestibular schwannoma OR two of: meningioma, schwannoma, glioma, neurofibroma, posterior subcapsular cataract, OR
• Unilateral vestibular schwannoma AND two of: meningioma, schwannoma, glioma, neurofibroma, posterior subcapsular cataract, OR
• Multiple meningiomas AND unilateral vestibular schwannoma OR two of: schwannoma, glioma, neurofibroma, cataract

6.1. Genetic Testing Strategy (The 3-Step Ladder)

1. Step 1: Next Generation Sequencing (NGS) Panel
   • Technique: Simultaneous sequencing of NF1, NF2, SPRED1, SMARCB1, LZTR1.
   • Sensitivity: > 95% for point mutations.
   • Turnaround: 4-8 weeks.
   • Failure Rate: Misses large deletions (5%) or deep intronic/splice site mutations.
2. Step 2: MLPA (Multiplex Ligation-dependent Probe Amplification)
   • Indication: If NGS is negative but clinical suspicion is high ("Microdeletion Syndrome").
   • Target: Large deletions/duplications (CNVs).
   • Yield: Detects the 5% of cases missed by NGS.
3. Step 3: RNA-Seq (cDNA Analysis)
   • Indication: "Mutation Negative" classic NF1.
   • Mechanism: Detects splicing errors caused by deep intronic variants.
   • Yield: Finds mutation in 90% of "Test Negative" patients.
   • Relevance: Needed for PGT-M (IVF) planning.

6.2. Imaging Protocol Details ("The NF Protocol")

1. Brain MRI (T1/T2/FLAIR)
   • UBOs: T2 hyperintensities (Globus Pallidus, Cerebellum). Do NOT enhance.
   • Optic Pathway Glioma (OPG): Thickening of optic nerve/chiasm. Variable enhancement.
   • Moyamoya: Flow voids in basal ganglia.
2. Whole Body MRI (WBMRI)
   • Role: Gold standard for tumor burden ("Tumor Load").
   • Technique: STIR (Short Tau Inversion Recovery) sequences suppress fat, making neurofibromas light up bright white.
   • Indication: Monitoring internal plexiform tumors (volumetric analysis).
3. PET-CT (FDG)
   • Role: Detecting Malignant Transformation (MPNST).
   • Cut-off: SUVmax > 3.5 suggests malignancy (Sensitivity 95%).
   • Caveat: Neurofibromas are metabolically active (SUV 1-3), so low-grade uptake is normal.

Biopsy Principles:

• Avoidance: Do not biopsy typical spots (scars heal poorly).
• Indication: Only for suspected malignancy.
• Technique: Core needle biopsy (multiple passes) under ultrasound guidance is preferred over open biopsy to avoid seeding or massive hemorrhage.

Imaging:

NF1:

• Brain MRI: Baseline and if symptoms, screen for optic pathway glioma
• Whole-body MRI: For plexiform neurofibromas (research setting)
• Spine MRI: If scoliosis or neurological symptoms
• PET scan: If MPNST suspected

NF2:

• Brain MRI with contrast: Screen for vestibular schwannomas, meningiomas
• Spine MRI: Screen for spinal tumors
• Auditory brainstem response: Assess hearing function
• Annual screening: From age 10-12 or earlier if family history

Monitoring Investigations:

NF1 Annual Monitoring:

• Blood pressure: Screen for pheochromocytoma
• Ophthalmological exam: Screen for optic pathway glioma
• Neurological exam: Assess for new deficits
• Skin exam: Monitor neurofibromas for changes
• Scoliosis screening: Clinical and X-ray if indicated

NF2 Annual Monitoring:

• Brain MRI: Monitor vestibular schwannomas and meningiomas
• Audiometry: Monitor hearing
• Neurological exam: Assess for new deficits
• Spine MRI: If symptoms or every 2-3 years

Complication Screening:

Differential Diagnosis (The Mimics)

1. Legius Syndrome:
   • Features: Cals + Freckling. NO Tumors.
   • Gene: SPRED1.
2. Noonan Syndrome:
   • Features: "Neurofibromatosis-Noonan Syndrome" (NFNS). Short stature, webbed neck, pulmonary stenosis.
   • Gene: PTPN11.
3. McCune Albright Syndrome:
   • Features: "Coast of Maine" spots (Jagged borders) vs NF1 "Coast of California" (Smooth borders).
   • Gene: GNAS.
4. Constitutional Mismatch Repair Deficiency (CMMRD):
   • Features: Looks like NF1 but with early colon/brain cancers.
   • Significance: Lethal if missed.

7. Management

           Suspicion of NF1
                  ↓
┌─────────────────────────────────────────┐
│        CLINICAL DIAGNOSIS               │
│  - Check 2021 Criteria (2 of 7)         │
│  - Slit Lamp (Lisch) / MRI (UBOs)       │
└─────────────────────────────────────────┘
                  ↓
          Criteria Met?
        ↙           ↘
      YES             NO
      ↓               ↓
┌─────────────┐   ┌────────────────────────┐
│ CONFIRM     │   │ CONSIDER DIFFERENTIAL  │
│ - Genetics  │   │ - Legius (SPRED1)      │
│ - Baseline  │   │ - Noonan               │
│   MRI/BP    │   │ - CMMRD                │
└─────────────┘   └────────────────────────┘
      ↓
┌─────────────────────────────────────────┐
│        SURVEILLANCE PATHWAY             │
│  - Annual BP (Pheo risk)                │
│  - Annual Skin Exam (MPNST check)       │
│  - Vision check (OPG)                   │
└─────────────────────────────────────────┘
      ↓
      COMPLICATION DETECTED?
      ↓
┌─────────────────────────────────────────┐
│         TREATMENT ARMS                  │
│  - Plexiform: Selumetinib (MEKi)        │
│  - MPNST: Wide Resection + Chemo        │
│  - Scoliosis: Bracing / Fusion          │
│  - Tibial Dysplasia: BMP + Rodding      │
└─────────────────────────────────────────┘

Management requires multidisciplinary approach with regular monitoring, early intervention for complications, and genetic counseling. Treatment is primarily supportive and surgical.

NEUROFIBROMATOSIS MANAGEMENT ALGORITHM
=======================================

Patient with suspected NF1/NF2
                |
                v
        Clinical Diagnosis (NIH criteria)
                |
                +-------------------+-------------------+
                |                   |                   |
            NF1                    NF2              Genetic Testing
                |                   |                   |
        Multidisciplinary Team  Multidisciplinary Team  - Confirm diagnosis
        - Genetics              - Genetics              - Family screening
        - Neurology             - Neurosurgery          - Prenatal options
        - Dermatology           - ENT
        - Ophthalmology          - Ophthalmology
        - Orthopedics           - Audiology
        - Psychology            - Psychology

                    NF1 MANAGEMENT
                        |
                        +-------------------+-------------------+
                        |                   |                   |
                Annual Monitoring      Complication        Treatment
                        |               Management          |
            - BP measurement      - Optic pathway glioma:  - Surgery for
            - Ophthalmology         Observation vs          disfiguring
            - Neurological exam      chemotherapy          neurofibromas
            - Skin exam           - MPNST: Surgery +      - Scoliosis
            - Scoliosis screen       radiotherapy          surgery
                                  - Pheochromocytoma:     - Learning
                                    Surgery                support
                                  - Hypertension:          - Psychological
                                    Medical management     support

                    NF2 MANAGEMENT
                        |
                        +-------------------+-------------------+
                        |                   |                   |
                Annual Monitoring      Tumor Management    Hearing Preservation
                        |                   |                   |
            - Brain MRI            - Vestibular schwannoma: - Hearing aids
            - Spine MRI              Watch, surgery, or    - Cochlear implant
            - Audiometry              radiotherapy          - BAHA
            - Neurological exam    - Meningioma: Surgery  - Sign language
            - Ophthalmology        - Spinal tumors:       - Communication
                                    Surgery                aids

                    GENETIC COUNSELING
                        |
                        v
            - Inheritance pattern (50% risk)
            - Variable expressivity
            - Prenatal diagnosis options
            - Preimplantation genetic testing
            - Family screening

NF1 Management:

Monitoring:

• Annual review: Multidisciplinary clinic
• Blood pressure: Every visit, screen for pheochromocytoma
• Ophthalmology: Annual in childhood, every 2 years in adults
• Neurological exam: Annual
• Skin exam: Annual, document changes
• Scoliosis: Screen annually in childhood

Optic Pathway Glioma:

• Observation: If asymptomatic, stable on imaging
• Chemotherapy: If progressive, symptomatic (carboplatin/vincristine)
• Surgery: Rarely, if causing severe visual loss
• Monitoring: Regular MRI and ophthalmology

Malignant Peripheral Nerve Sheath Tumor (MPNST) Surveillance:

• Risk: 8-13% Lifetime risk.
• Red Flags:
  • "Rapid Growth: Size doubles in less than 6 months."
  • "Pain: New, persistent pain (Night pain)."
  • "Hardness: Change from soft to hard firmness."
  • "Deficit: New numbness/weakness."
• Investigation: Whole Body MRI (STIR sequences). If suspicious -> PET-CT.
• Treatment: Wide excision (often amputation) + High Dose Radiotherapy. Chemotherapy (Doxorubicin) has limited effect.

The MEK Inhibitor Revolution (Selumetinib/Koselugo)

• Mechanism: Blocks MEK1/2, shutting down the overactive RAS-MAPK pathway.
• Indication: Inoperable Plexiform Neurofibromas in children (> 2 years).
• Efficacy: 70% of patients see tumor shrinkage (> 20% volume reduction).
• Side Effects:
  • "Skin Rash: Acneiform rash (Common)."
  • "Cardiac: Decreased Ejection Fraction (monitor Echo)."
  • "Ocular: Retinal Vein Occlusion / Retinal Detachment."
  • "CPK: Rhabdomyolysis risk."
• Impact: First ever FDA-approved drug for NF1 (2020).

Surgical Nuance (The Bleeding Risk):

• Plexiform neurofibromas are extremely vascular and fragile ("Friable").
• They interdigitate with normal nerves.
• Risk: Excision often causes massive haemorrhage and nerve sacrifice.
• Rule: Only operate if absolutely necessary (Airway, Disfigurement, Malignancy). Debulking is an option but regrowth is common.

Pheochromocytoma:

• Screening: Blood pressure, plasma metanephrines if hypertensive
• Treatment: Surgical resection after alpha-blockade
• Monitoring: Annual screening if at risk

Neurofibromas:

• Observation: Most require no treatment
• Surgery: If disfiguring, painful, or causing symptoms
• Laser: For small cutaneous neurofibromas
• Plexiform: Monitor for malignant transformation

Learning Disabilities:

• Assessment: Neuropsychological evaluation
• Support: Educational interventions, accommodations
• ADHD: Medical management if indicated

NF2 Management:

Vestibular Schwannoma:

• Observation: Small, asymptomatic tumors
• Surgery: If growing, causing symptoms, or threatening hearing
• Radiotherapy: Alternative to surgery, preserves hearing better
• Hearing preservation: Priority in management

Meningiomas:

• Observation: Small, asymptomatic
• Surgery: If growing or causing symptoms
• Multiple: May require multiple surgeries over lifetime

Spinal Tumors:

• Monitoring: Regular spine MRI
• Surgery: If causing cord compression or symptoms
• Multiple: May require staged surgeries

Hearing Management:

• Hearing aids: Conventional if useful
• Cochlear implant: If hearing lost, cochlear nerve intact
• BAHA: Bone-anchored hearing aid
• Sign language: Communication support

Genetic Counseling:

• Inheritance: 50% risk to offspring
• Prenatal diagnosis: Available if mutation known
• Preimplantation: Available for both NF1 and NF2
• Family screening: Screen at-risk relatives

8. Complications

Both NF1 and NF2 cause significant complications requiring vigilant monitoring and management. Early detection improves outcomes.

NF1 Complications:

Malignancies:

• MPNST: 5-10% lifetime risk, poor prognosis
• Optic pathway glioma: 15-20%, most benign but can cause visual loss
• Other CNS tumors: Gliomas, astrocytomas
• Pheochromocytoma: 0.1-5.7%, causes hypertension

Neurological:

• Learning disabilities: 30-60% of patients
• ADHD: 30-50% prevalence
• Seizures: 4-7% of patients
• Peripheral neuropathy: From neurofibromas

Skeletal:

• Scoliosis: 10-26%, may require surgery

• Tibial pseudarthrosis: 2-5%, difficult to treat

• Sphenoid wing dysplasia: Rare but characteristic

• Short stature: Common

• Short stature: Common. (GH deficiency vs Skeletal dysplasia).

Vascular Manifestations (The Silent Killer):

1. Hypertension: Very common. Causes:
   • Essential: Most common.
   • Renal Artery Stenosis: Fibromuscular dysplasia (FMD) of the renal artery. Screen with Renal MRA.
   • Pheochromocytoma: Rare but lethal. Screen with Plasma Metanephrines.
   • Aortic Coarctation: Rare.
2. Moyamoya Syndrome:
   • Pathology: Progressive stenosis of the distal ICA (Circle of Willis).
   • Result: Brain forms tiny collaterals ("Puff of Smoke" on Angio).
   • Risk: High stroke risk in children.
   • Treatment: Revascularisation surgery (EDAMS/Pial synangiosis).
3. Cerebrovascular Aneurysms: Increased risk. Screen if symptomatic.

Obstetric Considerations (High Risk Pregnancy):

• Hormonal Sensitivity: Neurofibromas have progesterone receptors.
  • Result: 80% of women see rapid tumor growth (size and number) during pregnancy.
  • Risk: Plexiform tumors can become massive and obstruct the airway or birth canal.
• Hypertension:
  • Preeclampsia: Risk is higher in NF1.
  • Pheochromocytoma: MUST be ruled out before delivery (Catastrophic hypertensive crisis during labour).
• Neuraxial Anaesthesia:
  • Contraindication: Spinal tumors (check MRI Spine before epidural).
  • Scoliosis: May make epidural placement impossible.

The Neurocognitive Phenotype (Hidden Disability):

• General Intelligence: Mean IQ is shifted left (Low Average, ~85-90), but Intellectual Disability (IQ less than 70) is rare (8%).
• Visuospatial Deficit: "Can't read a map"
  • "Clumsy child". Poor handwriting.
• ADHD: 50% prevalence. Respond well to Methylphenidate (Ritalin).
• Autism Spectrum Disorder (ASD):
  • Overlap: 30-40% of NF1 children have ASD traits.
  • Social: Difficulty interpreting social cues, poor eye contact.
• UBO Correlation: The presence of MRI UBOs correlates with cognitive impairment.

Advanced Orthopaedics (The Dystrophic Bone):

• Tibial Dysplasia:
  • The "Pencil Point": The tibia tapers to a sharp point at the fracture site.
  • Biology: The periosteum is infiltrated by neurofibroma tissue, preventing callus formation.
  • Failure: Plating fails. Rodding fails.
  • Salvage: Vascularized Fibular Graft or Amputation (Symes).
• Dystrophic Scoliosis:
  • Feature: "Scalloping" of the vertebral bodies (dural ectasia).
  • Rib Pencilling: Ribs become thin (twisted ribbon sign).
  • Surgery: High rate of pseudoarthrosis (hardware failure/pull-out). Needs anterior+posterior fusion.

NF2 Complications:

Hearing Loss:

• Bilateral: Progressive, from vestibular schwannomas
• Complete deafness: Common in advanced disease
• Impact: Significant on quality of life and communication

Neurological:

• Cranial nerve deficits: From schwannomas and meningiomas
• Spinal cord compression: From spinal tumors
• Hydrocephalus: From tumors blocking CSF flow
• Seizures: From brain tumors

Visual:

• Cataracts: Juvenile posterior subcapsular
• Visual loss: From optic nerve tumors or meningiomas

Functional:

• Balance problems: From vestibular dysfunction
• Facial weakness: From facial nerve schwannomas
• Swallowing difficulties: From lower cranial nerve involvement

9. Prognosis

Prognosis varies significantly between NF1 and NF2, and depends on complications. Early diagnosis and management improve outcomes.

NF1 Prognosis:

• Life expectancy: Reduced by 8-15 years
• Mortality: Primarily from malignancies (MPNST)
• Quality of life: Variable, depends on complications
• Most patients: Live relatively normal lives with monitoring

NF2 Prognosis:

• Life expectancy: Reduced, median survival 15-20 years from diagnosis
• Mortality: From complications of tumors
• Quality of life: Significantly impacted by hearing loss and neurological deficits
• Functional outcomes: Depend on tumor burden and management

Factors Affecting Prognosis:

• Early diagnosis: Enables monitoring and intervention
• Regular surveillance: Detects complications early
• Access to care: Multidisciplinary management improves outcomes
• Genetic counseling: Informed family planning
• Complication burden: More complications worsen prognosis

Long-term Outcomes:

• NF1: Most patients manage well with support
• NF2: Progressive disability from tumors
• Both: Require lifelong monitoring and management

10. Evidence

Major Guidelines:

• NIH Consensus Development Conference (1987): Diagnostic criteria for NF1
• International Consensus (2011): NF2 diagnostic criteria and management
• American Academy of Pediatrics (2019): Health supervision for NF1
• European NF Guidelines (2012): Management recommendations

Landmark Clinical Trials:

1. Selumetinib Trial (2020): MEK inhibitor for plexiform neurofibromas

   • Significant tumor volume reduction
   • First FDA-approved medical therapy for NF1
   • Well-tolerated, improves quality of life
   • PMID: 32053505

2. Optic Pathway Glioma Studies: Chemotherapy for OPG

   • Carboplatin/vincristine effective
   • Preserves vision in most patients
   • Better outcomes than observation alone
   • PMID: 21803784

3. MPNST Treatment Studies: Multimodal therapy

   • Wide surgical excision essential
   • Adjuvant radiotherapy improves local control
   • Chemotherapy for advanced disease
   • PMID: 31209658

4. Vestibular Schwannoma Management: Hearing preservation

   • Radiotherapy preserves hearing better than surgery
   • Early intervention improves outcomes
   • Monitoring vs intervention strategies
   • PMID: Various

5. Genetic Testing Studies: Diagnostic utility

   • High detection rates with modern techniques
   • Enables family screening and prenatal diagnosis
   • Improves diagnostic certainty
   • PMID: Various

Meta-Analyses:

• NF1 complications: Systematic review of prevalence (Uusitalo, 2016)
• NF2 management: Review of treatment strategies (Evans, 2009)
• Genetic testing: Utility in diagnosis and management (Yap, 2019)

Systematic Reviews:

• NF1 management: Comprehensive review (Ferner, 2007)
• NF2 tumors: Management strategies (Evans, 2005)
• Quality of life: Impact of NF1 and NF2 (Vranceanu, 2013)

Additional Trial Data:

• RAPID Trial (MEK Inhibitor for Cutaneous NF):
  • Drug: Selumetinib Gel (Topical).
  • Result: Disappointing. Poor penetration into the dermis.
• mTOR Inhibitor Trials (Sirolimus/Everolimus):
  • Rationale: mTOR is downstream of RAS.
  • Result: Failed to shrink Plexiform Neurofibromas (Phase II).
  • Niche: Some benefit in prolonging time to progression in OPG (chemo-sparing), but inferior to MEK inhibitors.
• Cablo-1 Trial (Cabozantinib):
  • Target: Tyrosine Kinase (c-Met, VEGFR2).
  • Population: Adult Plexiform Neurofibroma.
  • Result: 42% Partial Response rate. Useful alternative for adults (Selumetinib is only approved for children in many regions).

11. Patient

"What is neurofibromatosis?" Neurofibromatosis is a genetic condition that causes tumors to grow on nerves throughout your body. There are two types: NF1 (more common) and NF2 (rarer). NF1 causes skin changes like café-au-lait spots and bumps called neurofibromas, while NF2 mainly causes tumors in the brain and spine, especially affecting hearing. Both conditions run in families, but about half of cases happen by chance with no family history.

"How did I get it?" Neurofibromatosis is inherited from a parent in about 50% of cases - if a parent has it, each child has a 50% chance of inheriting it. In the other 50% of cases, it happens by chance due to a new genetic change (mutation) that wasn't inherited. It's not caused by anything you did or didn't do.

"What symptoms will I have?" Symptoms vary a lot between people, even in the same family. NF1 typically causes:

• Light brown skin spots (café-au-lait spots)
• Small bumps on the skin (neurofibromas)
• Learning difficulties in some people
• Sometimes tumors in the eyes or brain

NF2 typically causes:

• Hearing loss (often in both ears)
• Balance problems
• Tumors in the brain and spine

"How is it diagnosed?" Your doctor will examine you and look for specific features. For NF1, you need at least 2 of: 6 or more café-au-lait spots, neurofibromas, freckling in armpits/groin, eye findings, bone changes, or a family history. For NF2, it's usually diagnosed by finding bilateral hearing nerve tumors. Genetic testing can confirm the diagnosis.

"Is there a cure?" There's no cure, but there are treatments to manage symptoms and complications. Most people with NF1 live relatively normal lives with regular check-ups. Treatment focuses on:

• Monitoring for problems
• Removing tumors if they cause issues
• Managing learning difficulties
• Treating complications as they arise

"Will I need surgery?" Maybe, but not everyone does. Surgery might be needed if:

• Tumors are growing and causing problems
• Tumors are disfiguring or painful
• There are complications like spinal cord compression
• Hearing needs to be preserved in NF2

"What about my children?" If you have neurofibromatosis, each of your children has a 50% chance of inheriting it. Genetic counseling can help you understand the risks and options, including:

• Testing during pregnancy (if you want)
• Testing embryos before implantation (IVF)
• Early screening of children if they inherit it

"How often do I need check-ups?" You'll need regular monitoring, usually:

• Once a year for a full check-up
• More often if there are specific concerns
• Specialized scans (like MRI) as needed
• Eye exams, especially in childhood for NF1

"What should I watch for?" Call your doctor if you notice:

• A bump that's growing quickly or becoming painful
• New weakness or numbness
• Vision changes
• High blood pressure
• Hearing loss (especially in NF2)
• Any new or worsening symptoms

"Will I pass this to my children?"

• Yes, there is a 50% chance for each pregnancy.
• Option 1: Preimplantation Genetic Testing (PGT-M) - IVF to select unaffected embryos.
• Option 2: Prenatal Testing (CVS/Amnio) - Test the baby at 11-15 weeks.
• Option 3: No testing - Scan the baby after birth.

"What about cosmetic surgery?"

• Removing neurofibromas is possible but they can grow back.
• Insurance: In many countries, removing them is considered "Medical" if they cause pain or catch on clothing, but "Cosmetic" if purely for looks.
• Laser: CO2 laser can treat hundreds of small bumps at once ("Laser ablation").

"What happens when I turn 18? (Transition of Care)"

• The Gap: Many patients get lost between Paediatrics and Adult care.
• Adult Issues: Focus shifts from "Learning difficulties" to "Malignancy surveillance" and "Reproduction".
• Plan: You need a named "Adult Lead" (usually a Geneticist or Neurologist) before you leave the children's hospital.

"Can I drive?"

• Generally yes.
• Exceptions: If you have seizures (Brain tumor) or severe vision loss (Optic glioma). You must notify the DVLA/DMV if these complications develop.

"Can I live a normal life?" Yes, many people do. While neurofibromatosis can cause challenges, most people with NF1 manage well with support and monitoring. NF2 can be more challenging due to hearing loss, but with good management and support, people can lead fulfilling lives. Early diagnosis and regular care make a big difference.

Historical Context (The Elephant Man)

• Joseph Merrick (1862-1890): Famous "Elephant Man".
• Misdiagnosis: Long thought to have severe NF1.
• Correction: Modern testing (1986) suggests he actually had Proteus Syndrome (AKT1 mutation).
• Difference: Proteus causes disproportionate, asymmetric overgrowth (Mosaic), whereas NF1 is progressive and generalized.
• Relevance: Highlights the difficulty of diagnosing mosaic overgrowth syndromes.

The SPRINT Trial (Phase II) - NEJM 2020

• Question: Does Selumetinib shrink inoperable plexiform neurofibromas?
• Population: Children with NF1 + Symptomatic Inoperable PN.
• Result:
  • 66% had Partial Response (> 20% volume reduction).
  • Pain scores improved significanty.
  • Quality of Life scores improved.
• FDA Approval: Based on this trial, Selumetinib became the first approved drug.

12. Advanced Topics

12.1. NF1 vs NF2 vs Schwannomatosis: The Comprehensive Comparison

Key Clinical Discriminators:

• Bilateral vestibular schwannomas = NF2 until proven otherwise [21]
• Café-au-lait spots + Lisch nodules = NF1
• Multiple painful schwannomas without bilateral VS = Schwannomatosis [22]
• Cataracts in child/young adult + hearing loss = Think NF2 [23]

12.2. Café-au-Lait Spots: Detailed Clinical Analysis

Pathophysiology: Café-au-lait macules (CALMs) result from increased melanin production in melanocytes and keratinocytes, not increased melanocyte number. In NF1, loss of neurofibromin leads to RAS hyperactivation in melanocytes, driving increased melanogenesis via MITF (Microphthalmia-associated Transcription Factor) upregulation. [24]

Detailed Diagnostic Criteria (2021 Revision):

• Prepubertal: ≥6 CALMs > 5mm in greatest diameter
• Postpubertal: ≥6 CALMs > 15mm in greatest diameter
• Important: Measure in natural light with a ruler; photography recommended for documentation [25]

Clinical Characteristics:

• Color: Light to dark brown ("coffee with milk"), uniform pigmentation
• Borders: Smooth, well-defined (vs jagged in McCune-Albright)
• Distribution: Random, can occur anywhere including scalp
• Timing: 95% present by age 2; increase in size/number during first decade [26]
• Wood's lamp: Enhanced visibility in lighter skin tones

Differential Diagnosis of Multiple CALMs:

Clinical Pearls:

• 15-30% of normal population have 1-2 CALMs [27]
• Coast of California vs Coast of Maine: NF1 CALMs have smooth borders (California coastline), McCune-Albright has jagged borders (Maine coastline)
• Ethnicity matters: CALMs harder to detect in darker skin; may delay diagnosis by 2-3 years in Black/South Asian patients [28]
• Segmental NF1: Unilateral/localized CALMs suggest mosaicism; lower transmission risk

Red Flags for CMMRD (Lethal if Missed):

• CALMs + hypopigmented spots
• Family history of early cancer (less than 25 years)
• Personal history of pilomatricoma, intestinal polyps
• Requires urgent genetic testing (biallelic mismatch repair mutations) [29]

12.3. Optic Pathway Glioma: Evidence-Based Screening and Management

Epidemiology and Natural History:

• Prevalence: 15-20% of children with NF1 [30]
• Peak detection: 70% diagnosed before age 7; rare after age 10 [31]
• Symptomatic rate: Only 30-50% of OPGs cause symptoms requiring treatment [32]
• Location: Optic nerve (most common), chiasm, hypothalamus, optic radiations
• Histology: Pilocytic astrocytoma (WHO Grade I) - benign but location makes them dangerous

Natural History (Critical Data):

• Asymptomatic OPGs: 70% remain stable or regress spontaneously [33]
• Symptomatic OPGs: Symptoms usually develop within 2 years of detection [34]
• Vision loss: If untreated, 30-50% develop significant visual impairment [35]
• Spontaneous regression: Documented in 15-20% of cases, especially in younger children [36]

Screening Protocols: The Evidence Debate

The Controversy:

• Pro-MRI camp: Early detection prevents blindness
• Anti-MRI camp: Most OPGs are asymptomatic; MRI leads to overtreatment, parental anxiety, sedation risks

Current Evidence-Based Consensus (2023):

Clinical Red Flags Requiring MRI:

1. Vision changes: Decreased acuity, color vision loss (Ishihara testing)
2. Proptosis: Anteriorly displaced eye suggests optic nerve enlargement
3. Strabismus: New onset squint
4. Precocious puberty: Suggests hypothalamic involvement (age less than 8 girls, less than 9 boys)
5. Nystagmus: Often present from infancy; bilateral horizontal nystagmus
6. Afferent pupillary defect (RAPD): Unilateral optic nerve dysfunction
7. Optic disc pallor or edema: Fundoscopic finding [38]

Ophthalmological Screening Protocol (High Yield):

• Visual acuity: Age-appropriate (Teller cards less than 3yr, LEA symbols 3-5yr, Snellen > 5yr)
• Ishihara color plates: Red-green deficiency is early sign of optic nerve dysfunction
• Fundoscopy: Look for disc pallor, edema, or atrophy
• Visual fields: Confrontation (young children), automated perimetry (older)
• Optical coherence tomography (OCT): Retinal nerve fiber layer (RNFL) thinning predicts vision loss [39]

MRI Findings:

• T1: Hypointense to brain
• T2/FLAIR: Hyperintense, "fusiform enlargement" of optic nerve/chiasm
• Enhancement: Variable; enhancement does NOT predict progression [40]
• Volumetric analysis: Tumor volume > 1,400 mm³ associated with worse visual outcomes [41]

Treatment Indications (Not All OPGs Need Treatment!):

Observation:

• Asymptomatic OPG discovered on screening MRI
• Stable vision on serial testing
• No proptosis, no chiasmal compression

Treatment Required:

1. Progressive vision loss: > 2 lines on Snellen chart over 3-6 months
2. Significant baseline vision loss: less than 20/50 acuity
3. Proptosis with pain/cosmetic concern
4. Chiasmal involvement with visual field defects
5. Hypothalamic involvement with precocious puberty/diencephalic syndrome [42]

Treatment Options:

Prognosis:

• Vision preservation: 60-70% with chemotherapy maintain useful vision [47]
• Blindness risk: 10-15% become legally blind despite treatment [48]
• Tumor progression after age 10: Very rare; can stop surveillance [49]

Emerging Biomarkers:

• RNFL thickness on OCT: less than 70 μm predicts poor visual outcome [50]
• Volumetric MRI: Automated segmentation tracks tumor volume changes [51]
• MEK inhibitor era: Changing landscape; may become first-line [52]

12.4. Vestibular Schwannoma in NF2: Comprehensive Management

Pathophysiology: Loss of merlin (NF2 gene product) in Schwann cells of cranial nerve VIII leads to uncontrolled proliferation. Bilateral involvement is pathognomonic, suggesting germline mutation affecting all Schwann cell precursors. [53]

Clinical Presentation:

• Hearing loss: Progressive sensorineural, unilateral initially then bilateral (90%)
• Tinnitus: Constant ringing/buzzing (70%)
• Balance problems: Vestibular dysfunction, falls (50%)
• Facial weakness: Facial nerve compression (late finding, 10-20%)
• Hydrocephalus: From brainstem compression (rare, severe cases)

Diagnostic Evaluation:

• Audiometry: Sensorineural hearing loss, poor speech discrimination
• Auditory Brainstem Response (ABR): Prolonged wave I-V interval
• MRI brain with gadolinium: Gold standard; T1 post-contrast shows enhancing mass in cerebellopontine angle
• Vestibular testing: Caloric testing, videonystagmography

Tumor Growth Patterns:

• Average growth rate: 1-2mm per year [54]
• Variable: 20% show no growth over 5 years; 10% grow rapidly (> 5mm/year) [55]
• Predictors of rapid growth: Young age at diagnosis, larger initial size [56]

Management Strategy: The "Three-Way Choice"

1. Observation ("Watch and Wait"): Indications:

• Small tumors (less than 1.5cm)
• Stable hearing
• Elderly patients (slow growth)
• Tumor in only-hearing ear

Protocol:

• MRI every 6-12 months for 2 years, then annually if stable
• Audiometry every 6 months
• Intervene if growth > 2mm/year or hearing decline [57]

Outcomes:

• 60% remain stable on observation for 5+ years [58]

2. Surgery: Indications:

• Tumor > 3cm
• Brainstem compression
• Rapid growth
• Young patient with serviceable hearing (attempt preservation)
• Failed medical/radiotherapy

Surgical Approaches:

Hearing Preservation:

• Best with: Tumors less than 1.5cm, preoperative word recognition > 70%, no brainstem compression [59]
• Factors: Surgeon experience matters (high-volume centers have 2x better outcomes) [60]

3. Radiotherapy (Stereotactic Radiosurgery - SRS): Indications:

• Tumor 1.5-3cm
• Preserve hearing
• Poor surgical candidate
• Residual/recurrent tumor post-surgery

Technique:

• Gamma Knife: Most common
• CyberKnife: Frameless alternative
• Dose: 12-13 Gy to tumor margin (single fraction)

Outcomes:

• Tumor control: 95% at 5 years (growth arrest or shrinkage) [61]
• Hearing preservation: 50-70% maintain serviceable hearing [62]
• Facial nerve preservation: > 95% [63]

Complications:

• Delayed facial palsy: 5% at 2-5 years post-SRS [64]
• Trigeminal neuropathy: 5-10% (facial numbness/pain)
• Hydrocephalus: 2-5% (tumor swelling)
• Malignant transformation: Extremely rare (less than 0.1%) [65]

NF2-Specific Consideration:

• Bilateral disease: If both VSs need treatment, stagger interventions (treat worse side first, preserve better hearing)
• Only-hearing ear: Maximize preservation attempts (SRS + hearing aids + cochlear implant planning)

4. Medical Therapy (Bevacizumab): Revolutionary Development:

Mechanism: VEGF inhibitor reduces tumor vascularity and edema

Evidence:

• Landmark Trial (Plotkin et al., NEJM 2009): Bevacizumab in NF2 patients with progressive VS [66]
  • "Hearing response: 57% had hearing improvement"
  • "Radiographic response: 26% tumor shrinkage > 20%"
  • "Duration: Response maintained while on treatment"

Indications (Current Consensus):

• Progressive VS in NF2 with declining hearing
• Not surgical candidate
• Prefer hearing preservation over surgery/SRS

Dosing:

• 5mg/kg IV every 2-3 weeks (ongoing treatment required)

Limitations:

• Lifelong treatment: Tumor regrows if stopped
• Cost: $50,000-100,000/year
• Side effects: Hypertension (30%), proteinuria (20%), bleeding (rare), impaired wound healing
• Not curative: Stabilizes, rarely shrinks [67]

Outcomes:

• Hearing improvement: 50-60% of responders
• Tumor shrinkage: 20-40% of patients
• Quality of life: Significant improvement in hearing-related QoL [68]

Emerging Therapies:

• Brigatinib: ALK inhibitor, Phase II trials ongoing [69]
• Selumetinib: MEK inhibitor (failed to show benefit in NF2 VS, unlike NF1 plexiforms) [70]

Hearing Rehabilitation (When Preservation Fails):

Quality of Life in NF2:

• Deafness: Major driver of depression, social isolation [73]
• Employment: 60% unemployment rate in bilaterally deaf patients [74]
• Family planning: 50% transmission risk; PGD available [75]

12.5. Malignant Transformation: MPNST Surveillance and Management

Epidemiology of MPNST in NF1:

• Lifetime risk: 8-13% (vs 0.001% in general population = 1000-fold increase) [76]
• Age of onset: Peak 20-50 years (younger than sporadic MPNST) [77]
• Origin: 60-70% arise from pre-existing plexiform neurofibromas [78]
• Prognosis: 5-year survival 20-50% (worse than sporadic MPNST at 50-60%) [79]

Pathophysiology of Malignant Transformation:

The "Multi-Hit" Model:

1. Germline NF1 mutation (1st hit - inherited/de novo)
2. Somatic NF1 loss (2nd hit - Knudson's hypothesis) → Plexiform neurofibroma
3. Additional oncogenic hits in plexiform → MPNST
   • TP53 mutation: 75% of MPNSTs [80]
   • CDKN2A/B deletion (p16/p14): 50-75% [81]
   • SUZ12/EED loss (PRC2 complex): 70-90% (hallmark of MPNST) [82]
   • RAS/MAPK amplification: Additional RAS pathway activation
   • Copy number alterations: Chromothripsis (catastrophic chromosomal rearrangement) [83]

Molecular Biomarkers for MPNST:

• H3K27me3 loss: PRC2 inactivation leads to loss of this histone mark; diagnostic on immunohistochemistry [84]
• Ki-67 proliferation index: > 25% suggests high-grade malignancy [85]
• p53 overexpression: Nuclear accumulation in > 50% cells [86]
• S100 positivity: 50-70% (vs 100% in benign neurofibromas) - loss suggests dedifferentiation [87]

Clinical Red Flags for MPNST (The "5 Ps"):

Imaging for MPNST Detection:

1. Whole-Body MRI (WBMRI):

• Protocol: STIR (fat-suppressed) sequences, head to toe
• Purpose: Tumor burden mapping, annual surveillance in high-risk patients
• MPNST findings:
  • Peripheral enhancement (central necrosis)
  • Heterogeneous signal
  • Perilesional edema
  • Size > 5cm [92]

2. FDG-PET/CT (Gold Standard for MPNST Detection):

• SUVmax > 3.5: 89% sensitivity, 95% specificity for MPNST [93]
• SUVmax 1-3: Typical benign plexiform neurofibroma
• SUVmax > 5: Highly suspicious for malignancy, consider biopsy [94]
• Limitations: False positives with inflammation, infection, recent biopsy

3. MRI with DWI (Diffusion-Weighted Imaging):

• Low ADC (Apparent Diffusion Coefficient): Suggests high cellularity (malignancy) [95]
• ADC less than 1.0 x 10⁻³ mm²/s: Worrying for MPNST

Biopsy Considerations:

• Indication: SUVmax > 3.5, clinical red flags, imaging suspicious
• Technique: Core needle biopsy preferred (multiple passes, 16-18 gauge)
• Avoid: Incisional biopsy (seeding risk, disrupts surgical planes)
• Image-guided: CT or ultrasound guidance to sample highest SUV area [96]

Histopathology:

• Diagnosis requires: Malignant spindle cell tumor arising from peripheral nerve or neurofibroma
• Grading: High-grade (90% of NF1-associated MPNST) [97]
• Subtypes: Epithelioid (worse prognosis), heterologous differentiation (rhabdomyoblasts, cartilage)

Treatment of MPNST:

1. Surgery (Cornerstone):

• Goal: R0 resection (negative margins)
• Margins: Wide excision, 2-5cm margins if anatomically feasible [98]
• Reality: 50% have positive margins due to neurovascular involvement
• Amputation: Required in 20-30% of extremity MPNST for adequate margins [99]
• Reconstruction: Flap coverage, nerve grafting

Surgical Outcomes:

• R0 resection: 5-year survival 50-60%
• R1/R2 resection: 5-year survival 10-20% [100]

2. Radiotherapy:

• Indications: Adjuvant for all high-grade MPNST (regardless of margin status)
• Dose: 60-66 Gy in 30-33 fractions
• Timing: Within 6 weeks of surgery
• Benefit: Improves local control from 50% to 70%; minimal survival benefit [101]
• Modality: IMRT (Intensity-Modulated RT) preferred to spare normal tissue

3. Chemotherapy:

• Neoadjuvant: Considered for large (> 10cm) or unresectable tumors to downstage
• Adjuvant: Controversial; no clear survival benefit in most trials [102]
• Regimens:
  • "AIM (Doxorubicin + Ifosfamide + Mesna): Most common, 30-40% response rate [103]"
  • "Ifosfamide + Etoposide: Alternative"
  • "MAP (Methotrexate + Doxorubicin + Cisplatin): For osteosarcoma-like differentiation"
• Palliative: For metastatic disease (median survival 8-12 months)

4. Targeted Therapy (Experimental):

• MEK inhibitors (Selumetinib, Trametinib): Rational in NF1-MPNST (RAS pathway), but trials disappointing [104]
• HDAC inhibitors: Preclinical promise
• Immunotherapy (Checkpoint inhibitors): Low tumor mutational burden → poor response rates [105]
• PARP inhibitors: Under investigation for PRC2-deficient MPNST [106]

Prognosis (Survival Data):

Surveillance Protocol for MPNST Risk (High-Risk Patients):

High-Risk Defined:

• Multiple/large plexiform neurofibromas
• Internal plexiform neurofibromas
• History of rapid growth
• Family history of MPNST

Protocol:

• Annual clinical exam: Full skin and neurological exam
• Patient education: Self-monitoring for red flags
• WBMRI: Consider every 2-3 years in high-risk patients (controversial, not standard) [112]
• PET/CT: Only if clinical suspicion, NOT routine screening (false positive rate too high)

Metastatic MPNST:

• Sites: Lung (90%), bone (30%), liver (20%) [113]
• Timing: 40% have metastases at diagnosis; 50% develop within 2 years
• Surveillance: Chest CT every 3-6 months for 5 years post-treatment [114]

13. Emerging Therapies and Clinical Trials

13.1. MEK Inhibitors Beyond Selumetinib

Approved:

• Selumetinib (Koselugo): FDA/EMA approved 2020 for inoperable plexiform neurofibromas in children ≥2 years [115]

In Trials:

• Trametinib: MEK1/2 inhibitor, ongoing trials for OPG and plexiform [116]
• Mirdametinib/PD-0325901: Showed promise in Phase I/II [117]
• Cobimetinib: Combination with atezolizumab (immunotherapy) for MPNST [118]

Real-World Effectiveness:

• Response rate: 70% partial response (> 20% volume reduction) [119]
• Sustained response: 85% maintain response at 3 years [120]
• Quality of life: Pain reduction, improved mobility in 60% [121]

Challenges:

• Cost: $20,000-30,000/month
• Duration: Indefinite treatment (regrowth if stopped)
• Toxicity: Acneiform rash (80%), diarrhea (50%), cardiac dysfunction (10%) [122]

13.2. Other Targeted Therapies

13.3. Gene Therapy and Future Directions

CRISPR/Gene Editing:

• Preclinical: AAV-mediated NF1 gene delivery in mouse models shows promise [128]
• Challenge: Delivery to widespread Schwann cell population

RNA Interference:

• Targeting: Downregulate hyperactive RAS pathway downstream effectors

Immunotherapy:

• Checkpoint inhibitors: Disappointing in MPNST (low TMB) [129]
• CAR-T: Under investigation for NF1-associated tumors

Precision Medicine:

• Genotype-phenotype: Tailoring surveillance based on specific NF1 mutation [130]

14. Multidisciplinary Care and Guidelines

14.1. International Guidelines Summary

14.2. Multidisciplinary Team (MDT) Composition

Core Team:

• Clinical Genetics
• Neurology/Neurosurgery
• Dermatology
• Ophthalmology
• Orthopedic Surgery
• Oncology (Medical, Radiation)
• Radiology (Neuroradiology)

Extended Team:

• Psychology/Psychiatry
• Pain Management
• Audiology (NF2)
• ENT Surgery (NF2)
• Rehabilitation Medicine
• Genetic Counseling
• Specialist Nursing

Transition Services:

• Adolescent → Adult services (age 16-18)
• Reproductive counseling
• Career/employment support

15. Patient Resources and Support

15.1. Patient Organizations

International:

• Children's Tumor Foundation (CTF): www.ctf.org - Research funding, patient registry
• Neurofibromatosis Network: Global support
• NF2 BioSolutions: NF2-specific research and biobank

Regional:

• UK: Neurofibromatosis Association (NFAUK)
• USA: Children's Tumor Foundation chapters
• Europe: European NF Network (GENTURIS)
• Australia: Neurofibromatosis Australia

15.2. Clinical Trial Resources

• CTF Drug Discovery Initiative: www.ctf.org/research
• ClinicalTrials.gov: Search "neurofibromatosis"
• NF Registry: Patient registry for trial matching

16. References

1. Friedrich von Recklinghausen. Über die multiplen Fibrome der Haut und ihre Beziehung zu den multiplen Neuromen. Berlin: Hirschwald; 1882.

2. Gross AM, Wolters PL, Dombi E, et al. Selumetinib in Children with Inoperable Plexiform Neurofibromas. N Engl J Med. 2020;382(15):1430-1442. doi:10.1056/NEJMoa1912735. PMID: 32053505

3. Legius E, Messiaen L, Wolkenstein P, et al. Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021;23(8):1506-1513. doi:10.1038/s41436-021-01170-5. PMID: 33966033

4. Tora MS, Xenos D, Texakalidis P, et al. Treatment of neurofibromatosis 1-associated malignant peripheral nerve sheath tumors: a systematic review. Neurosurg Rev. 2020;43(2):513-523. doi:10.1007/s10143-019-01124-4. PMID: 31209658

5. Uusitalo E, Leppävirta J, Koffert A, et al. Incidence and mortality of neurofibromatosis: a total population study in Finland. J Invest Dermatol. 2015;135(3):904-906. doi:10.1038/jid.2014.465. PMID: 25354145

6. Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007;44(2):81-88. doi:10.1136/jmg.2006.045906. PMID: 17105749

7. Evans DG, Baser ME, O'Reilly B, et al. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br J Neurosurg. 2005;19(1):5-12. doi:10.1080/02688690500081206. PMID: 16147579

8. Plotkin SR, Blakeley JO, Evans DG, et al. Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria. Am J Med Genet A. 2013;161A(3):405-416. doi:10.1002/ajmg.a.35760. PMID: 23401320

9. Brems H, Beert E, de Ravel T, Legius E. Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol. 2009;10(5):508-515. doi:10.1016/S1470-2045(09)70033-6. PMID: 19410195

10. Tadini G, Fontana L, Lodovici S, et al. Café-au-lait spots and neurofibromatosis type 1: Identification of seven novel NF1 gene mutations. Dermatology. 2017;233(1):90-97. PMID: 28315868

11. De Schepper S, Boucneau J, Vander Haegen M, Messiaen L. Café-au-lait spots in neurofibromatosis type 1 and Legius syndrome: A review of the literature. J Dermatol. 2016;43(10):1121-1127. PMID: 27126547

12. Shah KN. The diagnostic and clinical significance of café-au-lait macules. Pediatr Clin North Am. 2010;57(5):1131-1153. doi:10.1016/j.pcl.2010.07.002. PMID: 20888463

13. Wimmer K, Yao S, Claes K, et al. Spectrum of single- and multiexon NF1 copy number changes in a cohort of 1,100 unselected NF1 patients. Genes Chromosomes Cancer. 2006;45(3):265-276. PMID: 16283621

14. Pasmant E, Sabbagh A, Spurlock G, et al. NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Hum Mutat. 2010;31(6):E1506-E1518. doi:10.1002/humu.21271. PMID: 20513137

15. Wimmer K, Rosenbaum T, Messiaen L. Connections between constitutional mismatch repair deficiency syndrome and neurofibromatosis type 1. Clin Genet. 2017;91(4):507-519. doi:10.1111/cge.12904. PMID: 27767209

16. Fisher MJ, Loguidice M, Gutmann DH, et al. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol. 2012;14(6):790-797. doi:10.1093/neuonc/nos076. PMID: 22474213

17. Campian J, Gutmann DH. CNS Tumors in Neurofibromatosis. J Clin Oncol. 2017;35(21):2378-2385. doi:10.1200/JCO.2016.71.7199. PMID: 28640703

18. de Blank PMK, Berman JI, Liu GT, et al. Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1. Neuro Oncol. 2013;15(8):1088-1095. PMID: 23658323

19. Listernick R, Ferner RE, Liu GT, Gutmann DH. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol. 2007;61(3):189-198. doi:10.1002/ana.21107. PMID: 17387725

20. Cassiman C, Legius E, Spileers W, et al. Ophthalmological assessment of children with neurofibromatosis type 1. Eur J Pediatr. 2013;172(10):1327-1333. doi:10.1007/s00431-013-2043-4. PMID: 23708214

21. Avery RA, Hwang EI, Ishikawa H, et al. Handheld optical coherence tomography during sedation in young children with optic pathway gliomas. JAMA Ophthalmol. 2014;132(3):265-271. doi:10.1001/jamaophthalmol.2013.7649. PMID: 24435762

22. Dalla Via P, Opocher E, Pinello ML, et al. Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program. Neuro Oncol. 2007;9(4):430-437. doi:10.1215/15228517-2007-031. PMID: 17704361

23. Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg. 1997;86(5):747-754. PMID: 9126887

24. Bouffet E, Jakacki R, Goldman S, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol. 2012;30(12):1358-1363. doi:10.1200/JCO.2011.34.5843. PMID: 22393084

25. Fangusaro J, Onar-Thomas A, Young Poussaint T, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol. 2019;20(7):1011-1022. doi:10.1016/S1470-2045(19)30277-3. PMID: 31174935

26. Merchant TE, Conklin HM, Wu S, Lustig RH, Xiong X. Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits. J Clin Oncol. 2009;27(22):3691-3697. doi:10.1200/JCO.2008.21.2738. PMID: 19581535

27. de Blank P, Bandopadhayay P, Haas-Kogan D, Fouladi M, Fangusaro J. Management of pediatric low-grade glioma. Curr Opin Pediatr. 2019;31(1):21-27. doi:10.1097/MOP.0000000000000717. PMID: 30475242

28. Avery RA, Ferner RE, Listernick R, et al. Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research. J Neurooncol. 2012;110(1):1-7. doi:10.1007/s11060-012-0944-y. PMID: 22899427

29. Xu J, Xia J, Zhang L. Systematic Review and Meta-Analysis of Optic Pathway Glioma in Neurofibromatosis Type 1: Prevalence and Treatment. Neurosurg Rev. 2025;48(1):25. PMID: 41314279

30. Kelly JP, Weiss AH. Detection of tumor progression in optic pathway glioma with and without neurofibromatosis type 1. Neuro Oncol. 2013;15(11):1560-1567. doi:10.1093/neuonc/not120. PMID: 24203893

31. Baser ME, Friedman JM, Wallace AJ, et al. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology. 2002;59(11):1759-1765. doi:10.1212/01.WNL.0000035638.74084.F4. PMID: 12473761

32. Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol. 2005;26(1):93-97. PMID: 15699726

33. Petrilli AM, Fernández-Valle C. Role of Merlin/NF2 inactivation in tumor biology. Oncogene. 2016;35(5):537-548. doi:10.1038/onc.2015.125. PMID: 25893302

34. Sagers JE, Brown AS, Vasilijic S, et al. Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma. Sci Rep. 2018;8(1):5437. doi:10.1038/s41598-018-23609-7. PMID: 29615716

35. Marinelli JP, Grossardt BR, Lohse CM, Carlson ML. Prevalence of sporadic vestibular schwannoma: Reconciling temporal bone, radiologic, and population-based studies. Otol Neurotol. 2019;40(3):384-390. doi:10.1097/MAO.0000000000002110. PMID: 30640242

36. Stangerup SE, Caye-Thomasen P, Tos M, Thomsen J. The natural history of vestibular schwannoma. Otol Neurotol. 2006;27(4):547-552. doi:10.1097/00129492-200606000-00018. PMID: 16791050

37. Régis J, Carron R, Park MC, et al. Wait-and-see strategy compared with proactive Gamma Knife surgery for patients with intracanalicular vestibular schwannomas: clinical article. J Neurosurg. 2010;113 Suppl:105-111. doi:10.3171/2010.8.GKS101058. PMID: 21121794

38. Slattery WH 3rd, Fisher LM, Iqbal Z, Oppenhiemer M. Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects. Otol Neurotol. 2004;25(5):811-817. PMID: 15354017

39. Nikolopoulos TP, Fortnum H, O'Donoghue G, Baguley D. Acoustic neuroma growth: a systematic review of the evidence. Otol Neurotol. 2010;31(3):478-485. doi:10.1097/MAO.0b013e3181d279a3. PMID: 20101168

40. Brooker JE, Fletcher JM, Dally MJ, Briggs RJ, Cousins VC, Malham GM. Management of vestibular schwannomas in patients with neurofibromatosis type 2: facial nerve outcomes for resection via retrosigmoid craniotomy. J Clin Neurosci. 2010;17(11):1393-1397. doi:10.1016/j.jocn.2010.03.029. PMID: 20674382

41. Sughrue ME, Yang I, Aranda D, Rutkowski MJ, Fang S, Cheung SW, Parsa AT. Beyond audiofacial morbidity after vestibular schwannoma surgery. J Neurosurg. 2011;114(2):367-374. doi:10.3171/2009.10.JNS091203. PMID: 19916461

42. Murphy ES, Suh JH. Radiotherapy for vestibular schwannomas: a critical review. Int J Radiat Oncol Biol Phys. 2011;79(4):985-997. doi:10.1016/j.ijrobp.2010.10.010. PMID: 21353158

43. Kondziolka D, Lunsford LD, McLaughlin MR, Flickinger JC. Long-term outcomes after radiosurgery for acoustic neuromas. N Engl J Med. 1998;339(20):1426-1433. doi:10.1056/NEJM199811123392003. PMID: 9811917

44. Hasegawa T, Kida Y, Kato T, Iizuka H, Kuramitsu S, Yamamoto T. Long-term safety and efficacy of stereotactic radiosurgery for vestibular schwannomas: evaluation of 440 patients more than 10 years after treatment with Gamma Knife surgery. J Neurosurg. 2013;118(3):557-565. doi:10.3171/2012.10.JNS12523. PMID: 23176330

45. Pollock BE, Lunsford LD, Kondziolka D, et al. Outcome analysis of acoustic neuroma management: a comparison of microsurgery and stereotactic radiosurgery. Neurosurgery. 1995;36(1):215-224. PMID: 7708163

46. Yang I, Sughrue ME, Han SJ, et al. Facial nerve preservation after vestibular schwannoma Gamma Knife radiosurgery. J Neurooncol. 2009;93(1):41-48. doi:10.1007/s11060-008-9747-x. PMID: 19011761

47. Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009;361(4):358-367. doi:10.1056/NEJMoa0902579. PMID: 19587327

48. Plotkin SR, Tonsgard JH, Ullrich NJ, et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol. 2012;33(6):1046-1052. doi:10.1097/MAO.0b013e31825e73f5. PMID: 22805104

49. Morris KA, Golding JF, Axon PR, et al. Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. Neurooncol Pract. 2016;3(4):281-289. doi:10.1093/nop/npv065. PMID: 31386066

50. Karajannis MA, Legault G, Fisher MJ, et al. Phase II study of everolimus in children with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol. 2014;16(2):292-297. doi:10.1093/neuonc/not150. PMID: 24311632

51. Welling DB, Packer MD, Chang LS. Molecular studies of vestibular schwannomas: a review. Curr Opin Otolaryngol Head Neck Surg. 2007;15(5):341-346. doi:10.1097/MOO.0b013e3282ef3a4a. PMID: 17823551

52. Carlson ML, Vivas EX, McCracken DJ, et al. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on Hearing Preservation Outcomes in Patients With Sporadic Vestibular Schwannomas. Neurosurgery. 2018;82(2):E35-E39. doi:10.1093/neuros/nyx511. PMID: 29309664

53. Deep NL, Carlson ML, Neff BA, et al. Cochlear implantation in adults with neurofibromatosis type 2: variables affecting auditory performance. Otol Neurotol. 2014;35(7):1158-1162. doi:10.1097/MAO.0000000000000311. PMID: 24751730

54. Colletti V, Shannon RV, Carner M, Veronese S, Colletti L. Outcomes in nontumor adults fitted with the auditory brainstem implant: 10 years' experience. Otol Neurotol. 2009;30(5):614-618. doi:10.1097/MAO.0b013e3181a864f2. PMID: 19546832

55. Lloyd SK, Glynn FJ, Rutherford SA, et al. Ipsilateral cochlear implantation after cochlear nerve preserving vestibular schwannoma surgery in patients with neurofibromatosis type 2. Otol Neurotol. 2014;35(1):43-51. doi:10.1097/MAO.0000000000000185. PMID: 24317206

56. Slattery WH, Brackmann DE, Hitselberger W. Hearing preservation in neurofibromatosis type 2. Am J Otol. 1998;19(5):638-643. PMID: 9752972

57. Vasilijic S, Colvin DC, Qi Y, et al. Hearing measurements in adults with neurofibromatosis type 2. J Neurosurg. 2012;116(2):317-323. doi:10.3171/2011.9.JNS11730. PMID: 22035272

58. Huang Y, Huang T, Chen X, et al. Natural course and treatment outcomes of NF2-associated vestibular schwannomas. Orphanet J Rare Dis. 2020;15(1):292. doi:10.1186/s13023-020-01567-x. PMID: 33121520

59. Goutagny S, Raymond E, Esquia-Medina GN, et al. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 1 patients with growing plexiform neurofibromas. J Neurooncol. 2011;103(3):581-586. doi:10.1007/s11060-010-0446-4. PMID: 21052776

60. Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman JM. Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology. 2005;65(2):205-211. doi:10.1212/01.wnl.0000168830.79997.13. PMID: 16043788

61. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002;39(5):311-314. doi:10.1136/jmg.39.5.311. PMID: 12011145

62. Farid M, Demicco EG, Garcia R, et al. Malignant peripheral nerve sheath tumors. Oncologist. 2014;19(2):193-201. doi:10.1634/theoncologist.2013-0328. PMID: 24470531

63. Lee W, Teckie S, Wiesner T, et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46(11):1227-1232. doi:10.1038/ng.3095. PMID: 25240281

64. Beert E, Brems H, Daniëls B, et al. Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes Cancer. 2011;50(12):1021-1032. doi:10.1002/gcc.20921. PMID: 21987445

65. De Raedt T, Beert E, Pasmant E, et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 2014;514(7521):247-251. doi:10.1038/nature13561. PMID: 25119042

66. Pemov A, Hansen NF, Sindiri S, et al. Patient age and tumor type define somatic mutation landscapes in neurofibromatosis type 1. Nat Commun. 2017;8(1):2054. doi:10.1038/s41467-017-02173-2. PMID: 29233960

67. Reilly KM, Kim A, Blakely J, et al. Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future. J Natl Cancer Inst. 2017;109(8):djx124. doi:10.1093/jnci/djx124. PMID: 28931291

68. Miao R, Wang H, Jacobson A, et al. Neutralizing tumor-promoting inflammation with polypeptide-dexamethasone conjugate for microenvironment modulation and cancer therapy. J Control Release. 2015;204:90-100. PMID: 25724275

69. Kahn J, Gillespie A, Tsokos M, et al. Radiation therapy in management of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Front Oncol. 2014;4:324. doi:10.3389/fonc.2014.00324. PMID: 25426421

70. Stucky CC, Johnson KN, Gray RJ, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol. 2012;19(3):878-885. doi:10.1245/s10434-011-1978-7. PMID: 21861229

71. Kroep JR, Ouali M, Gelderblom H, et al. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. Ann Oncol. 2011;22(1):207-214. doi:10.1093/annonc/mdq338. PMID: 20656792

72. Carli M, Ferrari A, Mattke A, et al. Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol. 2005;23(33):8422-8430. doi:10.1200/JCO.2005.01.4886. PMID: 16293873

73. Martin E, Lamba N, Flucke UE, et al. Non-cytotoxic systemic treatment in malignant peripheral nerve sheath tumors (MPNST): A systematic review from bench to bedside. Crit Rev Oncol Hematol. 2019;138:223-232. doi:10.1016/j.critrevonc.2019.04.007. PMID: 31092388

74. Davis LE, Bolejack V, Ryan CW, et al. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. J Clin Oncol. 2019;37(16):1424-1431. doi:10.1200/JCO.18.02374. PMID: 30998436

75. Dombi E, Baldwin A, Marcus LJ, et al. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. N Engl J Med. 2016;375(26):2550-2560. doi:10.1056/NEJMoa1605943. PMID: 28029918

76. Weiss B, Widemann BC, Wolters P, et al. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol. 2015;17(4):596-603. doi:10.1093/neuonc/nou235. PMID: 25323817

77. Widemann BC, Babovic-Vuksanovic D, Dombi E, et al. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatr Blood Cancer. 2014;61(9):1598-1602. doi:10.1002/pbc.25041. PMID: 24777722

78. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8(11):2281-2308. doi:10.1038/nprot.2013.143. PMID: 24157548

79. Kim A, Dombi E, Tepas K, et al. Phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias. J Clin Oncol. 2012;30(15):1787-1794. doi:10.1200/JCO.2011.37.8680. PMID: 22508829

80. Jessen WJ, Miller SJ, Jousma E, et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest. 2013;123(1):340-347. doi:10.1172/JCI60578. PMID: 23221341

81. Hersh JH; American Academy of Pediatrics Committee on Genetics. Health supervision for children with neurofibromatosis. Pediatrics. 2008;121(3):633-642. doi:10.1542/peds.2007-3364. PMID: 18310720

82. Stewart DR, Korf BR, Nathanson KL, Stevenson DA, Yohay K. Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2018;20(7):671-682. doi:10.1038/gim.2018.28. PMID: 29565419

83. Huson S, Evans D, Donnai D. A clinical study of neurofibromatosis 1 in north-west England. J Med Genet. 1989;26(11):712-721. doi:10.1136/jmg.26.11.712. PMID: 2511319

84. Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13(8):834-843. doi:10.1016/S1474-4422(14)70063-8. PMID: 25030515

85. Santoro C, Picariello S, Palladino F, et al. Neuropsychological profile of children and adolescents with neurofibromatosis type 1: a cross-sectional study. Orphanet J Rare Dis. 2020;15(1):239. doi:10.1186/s13023-020-01521-x. PMID: 32907596

17. References (continued)

13. Examination Focus (The Viva Vault)

Q1: What is the genetic mechanism of NF1? A: It is a loss-of-function mutation in the NF1 tumor suppressor gene on chromosome 17q11.2. The gene encodes Neurofibromin, a GAP (GTPase Activating Protein) that downregulates the RAS-MAPK pathway. Without it, RAS is constitutively active, leading to cell proliferation.

Q2: Explain the "Two-Hit Hypothesis" in NF1. A: Knudson's hypothesis states that individuals inherit one mutated copy (germline) and are heterozygous in all cells. Tumors form when the widespread second copy (wild type) is mutated (somatic hit) in a specific cell (e.g., Schwann cell), rendering it null for neurofibromin.

Q3: Features distinguishing NF1 from NF2? A:

• NF1: Ch17. Neurofibromin. Lisch Nodules. Neurofibromas. Optic Gliomas.
• NF2: Ch22. Merlin. Cataracts. Schwannomas (Bilateral VS). Meningiomas.

Q4: What are Lisch Nodules and do they affect vision? A: They are iris hamartomas (melanocytic). They appear dome-shaped and yellow-brown on slit lamp. They do NOT affect vision but are highly specific for diagnosis (> 90% of adults).

Q5: What is the risk of malignancy in NF1? A:

• MPNST: 8-13% lifetime risk. Arise from pre-existing plexiform neurofibromas.
• Gliomas: 15-20% risk of Optic Pathway Glioma.
• Pheochromocytoma: less than 1% general, but 5% in hypertensives.
• Breast Cancer: Risk is increased ($RR \approx 3.5$) in women less than 50.
• GIST: Increased risk of Gastrointestinal Stromal Tumors.

Q6: How do you manage a Plexiform Neurofibroma? A:

• Observation: If asymptomatic.
• Medical: MEK Inhibitor (Selumetinib) for inoperable symptomatic tumors (SPRINT trial).
• Surgical: Debulking is difficult due to vascularity and nerve infiltration. Total resection often sacrifices the nerve.

Q7: Signs of malignant transformation in a neurofibroma? A: "Rapid growth, Pain (especially night pain), Change in consistency (harder), New neurological deficit".

Q8: Explain the Tibial Pseudarthrosis pathology. A: Anterolateral bowing of the tibia presents at birth. The periosteum is abnormal (hamartomatous). If fracture occurs, union is blocked by this tissue. Treatment involves resection of the pseudarthrosis, BMPs, and rodding (Williams rod) or vascularized fibular graft.

Q9: What is the "Buttonhole Sign"? A: When palpating a cutaneous neurofibroma, it is soft and can be pushed down into the dermis (invaginated) like a button through a buttonhole. This confirms it is discrete and cutaneous, not subcutaneous/plexiform.

Q10: Why do NF1 patients get hypertension? A:

1. Essential (most common).
2. Renal Artery Stenosis (fibromuscular dysplasia).
3. Pheochromocytoma (catecholamine excess).
4. Aortic Coarctation (rare).

Q11: Can a woman with NF1 have a normal pregnancy? A: Yes, but it is high risk. Tumors grow rapidly. Hypertension is a risk. Epidurals may be difficult (scoliosis/spinal tumors). There is a 50% risk of transmission to the fetus.

Q12: What is "Segmental NF1"? A: It is Mosaicism. A post-zygotic mutation leads to features (spots/bumps) confined to one region of the body. Risk of transmission is low unless gonadal mosaicism is present.

Q13: List the criteria for NF2. A: Bilateral Vestibular Schwannomas is the hallmark. Alternatively, a first-degree relative plus unilateral VS or multiple other tumors (Meningioma, Schwannoma, Glioma, Cataract).

Q14: What is the "Cataract" of NF2? A: Juvenile Posterior Subcapsular Cataract (or cortical opacity). Often the first sign in children.

Q15: What is Neurofibromatosis-Noonan Syndrome? A: A phenotype with features of both (Spots + Webbed neck/Pulmonic stenosis). Usually due to a specific NF1 mutation, sometimes PTPN11.

Technical Appendix: Surgical Excision of Cutaneous Neurofibroma

1. Indication: Pain, disfigurement, bleeding.
2. Anaesthesia: Local (Lidocaine with Adrenaline).
3. Incision: Elliptical excision around the lesion (include overlaying skin).
4. Dissection: The tumor separates easily from the subcutaneous fat.
5. Haemostasis: Bipolar diathermy (can be vascular).
6. Closure: Deep dermal (3-0 Monocryl) and Subcuticular (4-0 Monocryl).

Technical Appendix: Management of Plexiform Neurofibroma (Debulking)

1. Setting: General Anaesthesia. Cross-match blood (high bleeding risk).
2. Exposure: Wide exposure of the involved region.
3. Dissection:
   • Identify the normal nerve entering and exiting the mass (if possible).
   • Use a nerve stimulator to identify functional fascicles.
   • The tumor infiltrates the nerve; a plane is often absent.
4. Resection:
   • Perform an intra-capsular debulking if the nerve must be saved.
   • Perform en-bloc resection if the nerve is non-functional or sacrificed (requires graft).
5. Haemostasis: Critical. Use Harmonic scalpel, Ligasure, or multiple transfixion sutures.
6. Closure: Drains are mandatory (large dead space).

14. Clinical Cases (Scenario Based Learning)

Case 1: The Child with Spots

Presentation: A 5-year-old girl is brought in by her mother who noticed "dirty marks" on her back. Examination reveals 8 café-au-lait macules (> 5mm) and freckling in the axilla. She is otherwise well and meeting milestones. Discussion:

• Does she meet criteria? Yes (CALs + Freckling = 2 criteria).
• Next Step: Ophthalmology referral (exclude Lisch/OPG). Genetic testing (confirm NF1 vs Legius).
• Counseling: Reassure parents that severe complications (MPNST/Tibial dysplasia) are rare. Most children lead normal lives.

Case 2: The Teenager with Back Pain

Presentation: A 14-year-old boy with known NF1 presents with worsening back pain and "uneven shoulders". He has noticed his right leg feels shorter. Discussion:

• Diagnosis: Dystrophic Scoliosis. The "short leg" may be due to pelvic obliquity or a tibial pseudarthrosis (though usually presents earlier).
• Red Flag: Rapid progression is typical in dystrophic curves.
• Action: Whole Spine MRI (screen for dural ectasia and spinal tumors). Orthopaedic referral for likely fusion.

Case 3: The Rapidly Growing Lump

Presentation: A 32-year-old man with NF1 complains of a lump in his thigh that has been there for years (Plexiform) but has suddenly doubled in size over 3 months and is now painful at night. Discussion:

• Diagnosis: Suspect MPNST until proven otherwise.
• Red Flags: Rapid growth, Night pain, Hard consistency.
• Action: Urgent PET-CT and Biopsy. Do NOT simply excise (high risk of seeding).
• Prognosis: If MPNST, 5-year survival is less than 50%.

Case 4: The Pregnant Woman

Presentation: A 28-year-old woman with NF1 is 12 weeks pregnant. She is worried about her baby and her own health. Discussion:

• Risks to Mom: Hypertension (Rule out Pheochromocytoma NOW). Tumor growth (Progesterone effect).
• Risks to Baby: 50% chance of inheritance.
• Action: Genetic counseling. Monitoring BP. Anesthesiology review (Spine MRI if considering epidural).